Studies have reported that routine UGT1A1 testing is cost effective, reducing the incidence of severe neutropenia and hospitalization costs, especially in patients receiving high-dose irinotecan or those undergoing dose escalation [39]. Here, UGT1A1 is linked to neutropenia.